ProtoKinetix evaluates major European proposals to expand AAGP technology use

ProtoKinetix Inc. (PKTX) has been approached by a European biopharma investment group with a series of proposals to develop commercial partnerships in the pharmaceutical/cosmetic arenas. In order to support these initiatives, it has been strongly suggested that our European technology (AAGP™) should be more visibly showcased within the European community. This would include an awareness program leading up to a sponsorship for a listing on the AIM, London Stock Exchange.

ProtoKinetix believes that these events are natural synergies due to the strong European origins of the AAGP™ family of molecules. AAGP™ was first created in the laboratories of the University of Rouen, France. Human embryonic stem cell preservation was successfully tested at the University of Helsinki, Finland. The University of Bordeaux proved the ability of AAGP™ to defend skin cells from a wide range of hostile conditions. The National Institute of Chemistry, in France, showed that these molecules were non-toxic in standard concentrations.

ProtoKinetix’ President and CEO states that, “in addition to the proposals currently being evaluated, the company has a number of excellent opportunities to enter into new collaborations with world leading biotechnology investigators and companies to expand the use and applications of the AAGP™ family of molecules. Though these European collaborations and partnerships, we are confident of both financial and scientific success”.